Literature DB >> 28763121

Proportion of daily capillary blood glucose readings required in the target range for target glycaemic control: shift of focus from target range to proportion in range.

S Sivasubramaniyam1,2, S A Amiel1,3, P Choudhary1,3.   

Abstract

AIM: Most guidelines provide people with Type 1 diabetes with pre- and post-meal capillary blood glucose (CBG) targets to achieve optimal glycaemic control. We evaluated the proportion of daily CBG readings between 4 and 10 mmol/l in people achieving different HbA1c levels.
METHOD: We analysed CBG data from routine pump/meter downloads from 201 adults treated with continuous subcutaneous insulin infusion (CSII) at a single hospital clinic. Exclusion criteria were CSII < 6 months, < 3 CBG/day, pregnancy, haemoglobinopathy and continuous sensor use. People were categorized into three groups based on HbA1c : < 58 mmol/mol, < 7.5% (n = 58); 58-74 mmol/mol, 7.5-8.9% (n = 107); and ≥ 75 mmol/mol, ≥ 9.0% (n = 36).
RESULTS: Participants had a mean age of 43 ± 13 years and mean HBA1c of 64 mmol/mol (8.0 ± 1.1%). 47% of people started CSII for raised HbA1c , 25% due to hypoglycaemia and the rest during pregnancy. Downloads contained a mean of 22 ± 6.8 days of data per participant. CBG frequency was similar between the three groups (5.6 ± 2.0, 5.6 ± 1.9 and 5.4 ± 1.2 CBG/day; P = 0.468). The proportion of CBG readings between 4 and 10 mmol/l (72-180 mg/dl) was 57.3 ± 25.4%, 50.6 ± 11.1% and 39.9 ± 16.5% (P < 0.0001); < 4 mmol was 13.8%, 8.8% and 4.4% (P < 0.0001) and > 10 mmol/l was 28.9 ± 16.5%, 40.6 ± 12.1% and 55.6 ± 17.9% (P < 0.0001) in the three groups respectively.
CONCLUSIONS: Participants achieving HBA1c < 58 mmol/mol (< 7.5%) had ~ 60% of CBG readings in range (4-10 mmol/l), with up to 30% of readings > 10 mmol/l. This target of achieving 60% or more readings within target, and being permissive with up to 30% readings > 10 mmol/l may be a novel target for people with diabetes, and may reduce anxiety associated with readings out of range.
© 2017 Diabetes UK.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28763121     DOI: 10.1111/dme.13438

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  3 in total

Review 1.  Defining Outcomes for β-cell Replacement Therapy in the Treatment of Diabetes: A Consensus Report on the Igls Criteria From the IPITA/EPITA Opinion Leaders Workshop.

Authors:  Michael R Rickels; Peter G Stock; Eelco J P de Koning; Lorenzo Piemonti; Johann Pratschke; Rodolfo Alejandro; Melena D Bellin; Thierry Berney; Pratik Choudhary; Paul R Johnson; Raja Kandaswamy; Thomas W H Kay; Bart Keymeulen; Yogish C Kudva; Esther Latres; Robert M Langer; Roger Lehmann; Barbara Ludwig; James F Markmann; Marjana Marinac; Jon S Odorico; François Pattou; Peter A Senior; James A M Shaw; Marie-Christine Vantyghem; Steven White
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

Review 2.  Defining outcomes for β-cell replacement therapy in the treatment of diabetes: a consensus report on the Igls criteria from the IPITA/EPITA opinion leaders workshop.

Authors:  Michael R Rickels; Peter G Stock; Eelco J P de Koning; Lorenzo Piemonti; Johann Pratschke; Rodolfo Alejandro; Melena D Bellin; Thierry Berney; Pratik Choudhary; Paul R Johnson; Raja Kandaswamy; Thomas W H Kay; Bart Keymeulen; Yogish C Kudva; Esther Latres; Robert M Langer; Roger Lehmann; Barbara Ludwig; James F Markmann; Marjana Marinac; Jon S Odorico; François Pattou; Peter A Senior; James A M Shaw; Marie-Christine Vantyghem; Steven White
Journal:  Transpl Int       Date:  2018-04       Impact factor: 3.782

Review 3.  Time in range: A best practice guide for UK diabetes healthcare professionals in the context of the COVID-19 global pandemic.

Authors:  E G Wilmot; A Lumb; P Hammond; H R Murphy; E Scott; F W Gibb; J Platts; P Choudhary
Journal:  Diabet Med       Date:  2020-11-16       Impact factor: 4.213

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.